June 18, 2019 06:27 AM EDTUpdated July 3, 10:08 AM

AstraZeneca/Merck win EU approval for frontline maintenance treatment of ovarian cancer, months after FDA endorsement

AstraZeneca and Merck’s PARP inhibitor Lynparza has carved itself a niche in Europe.

Five months after getting a speedy approval from the US regulator …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As­traZeneca/Mer­ck win EU ap­proval for front­line main­te­nance treat­ment of ovar­i­an can­cer, months af­ter FDA en­dorse­ment